Literature DB >> 1852430

The effect of chronic orthopedic infection on quality of life.

M D Cheatle1.   

Abstract

The patient with chronic orthopedic infection presents a unique challenge to the orthopedic surgeon. The orthopedic surgeon must not only possess an expertise in constantly evolving diagnostic and treatment techniques but also be able to identify numerous related problems and direct the patient in receiving the most appropriate treatment. This demands a commitment of time by the treating surgeon to the individual patient to properly assess the need for support, the extent of psychologic distress, the intensity of pain, and the requirement for medication management. The effective utilization of a multidisciplinary team of health care providers (e.g., specialists in infectious disease, physical medicine and rehabilitation, psychiatry, nursing, pharmacology) can provide an optimal treatment program for this multifaceted problem and maximize the potential for a favorable outcome.

Entities:  

Mesh:

Year:  1991        PMID: 1852430

Source DB:  PubMed          Journal:  Orthop Clin North Am        ISSN: 0030-5898            Impact factor:   2.472


  4 in total

1.  [Therapy of chronic osteomyelitis: soft tissues as "key to success"].

Authors:  R M Sellei; P Kobbe; M Knobe; P Lichte; T Dienstknecht; S W Lemmen; H-C Pape
Journal:  Orthopade       Date:  2012-01       Impact factor: 1.087

2.  On the generalizability of statistical expressions of health related quality of life instrument responsiveness: a data synthesis.

Authors:  M M Murawski; P A Miederhoff
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

3.  Infected pseudarthrosis - A review of 75 cases Pseudarthroses infectées - Révision de 75 cas.

Authors:  J A Teixeira; A Garruço; S Oliva
Journal:  Eur J Orthop Surg Traumatol       Date:  1996-05

4.  Cost-Effectiveness Study of One-Stage Treatment of Chronic Osteomyelitis with Bioactive Glass S53P4.

Authors:  Jan Geurts; Tom van Vugt; Eline Thijssen; Jacobus J Arts
Journal:  Materials (Basel)       Date:  2019-09-30       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.